Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A global Phase III clinical trial evaluating the efficacy and safety of combination of regdanvimab (CT-P59) and CT-P63 for patients with mild-to-moderate symptoms of COVID-19

Next Previous
Search
Trial Profile

A global Phase III clinical trial evaluating the efficacy and safety of combination of regdanvimab (CT-P59) and CT-P63 for patients with mild-to-moderate symptoms of COVID-19

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 08 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Regdanvimab and CT P63 antibody cocktail-Celltrion (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use

    • Most Recent Events

    • 06 Feb 2022 According to a Celltrion media release, it has submitted an Investigational New Drug (IND) application to conduct a global Phase III clinical trial evaluating the efficacy and safety of an inhaled COVID-19 antibody cocktail therapy for patients with mild-to-moderate symptoms of COVID-19.The trial is expected to enrol 2,200 patients globally.
    • 12 Jan 2022 New trial record
    • 03 Jan 2022 According to a Celltrion media release, company plans to discuss to discuss this trial with regulatory agencies worldwide in the near future.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top